Clinical Trials
3 trialsNCT07581834 2026-05-12
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Fujian Cancer Hospital
Phase 2 Recruiting
NCT07101159 2025-08-03
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT03024580 2019-08-15
MEGA
Instituto Nacional de Cancer, Brazil
Phase 2 Unknown